Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics, Inc. was a genomic medicine company founded in 1995 and based in the San Francisco Bay Area, with headquarters in Brisbane, California. It was originally named Sangamo BioSciences and adopted the Sangamo Therapeutics name in January 2017. Its core technology was the zinc finger protein platform, used to build zinc finger nucleases for genome editing and transcription factors for gene regulation.

The company developed a pipeline of gene therapy, cell therapy and genome regulation programs. Its lead clinical programs included ST-920 (isaralgagene civaparvovec), an adeno-associated virus gene therapy for Fabry disease, along with earlier programs in neurological disease. Sangamo had collaborations with several large biopharmaceutical companies, including Biogen, Pfizer, Sanofi and Kite Pharma.

Sangamo went public in 2000 and its common stock traded on Nasdaq under the symbol SGMO. Like many clinical-stage biotechnology companies, it recorded recurring operating losses and depended on partnership payments and capital raises. Its liquidity became constrained in the years before the delisting.

Nasdaq suspended trading in Sangamo's common stock on May 5, 2026, after which it traded on the OTCID Basic Market as SGMOQ. On June 23, 2026 the company filed a voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the District of Delaware and continued to operate as a debtor-in-possession. A Nasdaq Hearings Panel denied its request to continue listing on July 14, 2026.

The bankruptcy court approved bidding procedures on July 14, 2026, and an auction was held on August 10, 2026, with PTC Therapeutics selected as the successful bidder. An asset purchase agreement was signed on August 25, and the court entered a sale order on September 2, 2026. The sale closed on September 17, 2026.

Under the agreement PTC acquired substantially all assets primarily related to ST-920 for $111 million in cash at closing, up to $100 million in contingent milestone payments, and the assumption of certain liabilities. These proceeds went to the bankruptcy estate rather than directly to shareholders. Nasdaq filed a Form 25 on September 17, 2026, and the delisting became effective on September 27, 2026.